Holen Sie sich die Stockscreener-App
4.86
2.97%
0.14
Schlusskurs vom Vortag:
$4.72
Offen:
$4.9071
24-Stunden-Volumen:
3,838
Relative Volume:
0.13
Marktkapitalisierung:
$38.86M
Einnahmen:
$85,000
Nettoeinkommen (Verlust:
$-22.16M
KGV:
-0.129
EPS:
-37.672
Netto-Cashflow:
$-6.29M
1W Leistung:
-9.16%
1M Leistung:
+2.53%
6M Leistung:
-54.19%
1J Leistung:
-62.33%
1-Tages-Spanne:
$4.70
$4.9071
1-Wochen-Bereich:
$4.70
$5.40
52-Wochen-Spanne:
$3.85
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
4.86 | 37.74M | 85,000 | -22.16M | -6.29M | -37.67 |
ABT
Abbott Laboratories
|
105.77 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.29 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
271.90 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.12 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.11 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Q1 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
PAVmed Inc. Series Z Warrant (PAVMZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
PAVmed Inc (PAVMW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Completion of Louisville VA Medical Center delayed until 2027 - AOL.com
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the ClosePost-Earnings Reaction - vinanet.vn
WVU PCH updates their signage and navigation - AOL.com
VA touts psilocybin trial for vets, but relief could take time - AOL.com
Verasonics Appoints New Senior Vice President, Research & Development - AOL.com
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfitability Analysis - vinanet.vn
Former President of DePuy Synthes U.S. Joins Peptilogics Board - AOL.com
PAVmed Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-08-17 - Seeking Alpha
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
PAVM Q1 2026 Earnings: EPS of -$4.42 Misses Consensus by 519%; Shares Rally 9.7%ROA Comparison - vinanet.vn
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings - Stock Titan
PAVmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses - Quiver Quantitative
PAVmed Inc. 2026: Revenue $33K, EPS ($0.87) — 10-Q Summary - TradingView
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Vesalio Announces FDA 510(k) Clearance of pVasc NET, a Next-Generation Peripheral Mechanical Thrombectomy Device with Integrated Distal Filter - AOL.com
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
PAVmed Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
PAVmed Inc (NASDAQ: PAVM) Share Price, PAVM Stock News, PAVM Share Price & Updates - Kalkine
PAVM Q2'26 Earnings: revenue estimate is 48.00K USD - TradingView
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):